Business Wire

Hilton Global Trends Report Unpacks Surprising Ways the Pandemic Changed People, Profiles Expected 2022 Traveler Passions

4.11.2021 15:01:00 EET | Business Wire | Press release

Share

There is no doubt that the pandemic modified travel – but that’s just part of the story. Today, Hilton released a global trends report unpacking how the pandemic changed people. “The 2022 Traveler: Emerging Trends and the Redefined Traveler, a Report from Hilton dives into an important truth: in two years, people’s lives were dramatically altered and that radically changed people.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211104005070/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Hilton Global Trends Report Unpacks Surprising Ways the Pandemic Changed People, Profiles Expected 2022 Traveler Passions (Photo: Business Wire)

As a company that has welcomed 3 billion guests in its more than 100-year history, Hilton showcases within the report how it is evolving alongside the changing traveler, tackling areas of expertise such as:

  • Fitness: How app workouts and new fitness routines have changed people’s approach to where, when and how they exercise on-the-road.
  • Spa: How the increased focus on wellness is evolving the spa, as well as the holistic, hotel experience.
  • Food and beverage: How the sourdough bread trend of 2020 is translating into more demand for culinary adventures; how tequila sales are dramatically outpacing the pre-pandemic bar shelf leader, bourbon.
  • Sustainability: From cooking in solar ovens to exploring using electric-assist bikes, how 18 months in lockdown is driving a renewed passion for a healthy planet.
  • Design: How DIY improvements, plant-crazed hobbies and working from patios is changing people’s perspective of hotel design.
  • Amenities: How the rise in pet ownership during the pandemic is leading to increased interest in pet travel and the development of hotel dog parks, pup perks and more.
  • Loyalty: How the rise of loyalty programs – across all sectors – is leading to better personalization and benefits to customers.

“The world – and the hospitality industry – went through so much in the last two years. And as we’ve uncovered in this report, travelers’ needs and interests have shifted too,” said Chris Nassetta, president and chief executive officer, Hilton. “At Hilton, we’ve been incredibly focused on delivering the experiences our guests are looking for, through every up and down we’ve faced. As we look to the future, I am optimistic about what lies ahead – travel is certainly returning, and we’re excited to build on that momentum.”

The Report highlights dozens of eye-opening travel and behavioral trends that are leading to innovations both inside and outside of the hotel. While each trend details specific insights and data driving change, four consistent themes emerged that summarize the new, pandemic-changed traveler:

  • Amid Chaos, People Found Efficiencies – And Will Be Looking for the Same in Travel: People have embraced efficiencies in many aspects of life and will be looking for similar conveniences in their travels, like contactless check-in and check-out and digital keys.
  • Overall Focus on Wellness Will Span Beyond the Gym: With a reimagined workplace and new routines and habits in place, travelers will be looking for more grounding and balance in their travel schedules.
  • They Nurtured New and Existing Passions and Will Have More Refined Tastes and Preferences: New and refreshed hobbies are leading to a more informed, sophisticated, and, in some cases, in-shape 2022 traveler. People are anticipated to pack their passions, driving demand for new trends in fitness, culinary options and unique travel experiences.
  • A New Sense of Caring Has Emerged – And Is Expected to Strengthen: The pandemic separated families and friends, which is leading to a prioritization of reunion and reconnection travel in 2022. Beyond their inner circles, travelers are expected to care more about sustainability and community efforts – and are looking to remain loyal to brands, companies and organizations that align with their values.

The pandemic’s impact on the travel industry has been well documented. However, it’s equally important to recognize the psychological impact the pandemic had, and will continue to have, on travelers for years to come,” said Dr. Kate Cummins, Psy.D, a clinical psychologist who recognizes travel as an important component of mental well-being. “The traveler may have changed, but the benefit of travel remains the same – increased emotional health and wellness, and after a tough two years, that’s something we all need.”

For more information and for a complete view of the report, visit Newsroom.Hilton.com/TrendsReport. To start planning 2022 travels, visit Hilton.com.

About Hilton

Hilton (NYSE: HLT) is a leading global hospitality company with a portfolio of 18 world-class brands comprising more than 6,700 properties and more than 1 million rooms, in 122 countries and territories. Dedicated to fulfilling its founding vision to fill the earth with the light and warmth of hospitality, Hilton has welcomed more than 3 billion guests in its more than 100-year history, earned a top spot on the 2021 World’s Best Workplaces list, and was named the 2020 Global Industry Leader on the Dow Jones Sustainability Indices. In 2020, Hilton CleanStay was introduced, bringing an industry-defining standard of cleanliness to hotels worldwide. Through the award-winning guest loyalty program Hilton Honors, the nearly 123 million members who book directly with Hilton can earn Points for hotel stays and experiences money can’t buy. With the free Hilton Honors app, guests can book their stay, select their room, check in, unlock their door with a Digital Key and check out, all from their smartphone. Visit newsroom.hilton.com for more information, and connect with Hilton on Facebook, Twitter, LinkedIn, Instagram and YouTube.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

NEWS MEDIA ONLY:
Colleen Hart
Director, Global Enterprise Communications
Colleen.Hart@Hilton.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye